52221-08-6

Upstream product

• 75-65-0 tert-butyl alcohol 
• 79-37-8 oxalyl dichloride 
• 627-91-8 adipic acid monomethyl ester 
• 98946-18-0 tert-Butyl 2,2,2-trichloroacetimidate 

Downstream Products

• 52221-07-5 6-(tert-butoxy)-6-oxohexanoic acid 
• 1373278-36-4 methyl 2-(5-tert-butoxy-5-oxopentyl)-4-oxo-3-p-tolyl3,4-dihydroquinazoline-7-carboxylate 
• 1373278-34-2 2-(6-tert-butoxy-6-oxohexanamido)-4-(methoxycarbonyl)benzoic acid 
• 69868-48-0 4-Biphenylcarbonsaeure-<6-(7-tert-butyloxycarbonyl-3-hydroxy-4-methyl-1-heptenyl)-3-oxo-2-oxa-7-bicyclo<3.3.0>octylester> 
• 69868-20-8 4-Biphenylcarbonsaeure-<6-<(4-tert-butyloxycarbonylbutyl)carbonylvinyl>-3-oxo-2-oxa-7-bicyclo<3.3.0>octylester> 

Relevant academic research and scientific papers

PANTETHEINE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I), (II), or (II'): (I), (II), (II'), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

QUINAZOLINONE-TYPE COMPOUNDS AS CRTH2 ANTAGONISTS

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH2 receptor.

Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors

Inhibitors of the cytosolic phospholipase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where X, Z, R1, R2, R3, R4, Ra and Rb are as defined in the specification.

Alpha-and beta-substituted trifluoromethyl ketones as phospholipase inhibitors

Inhibitors of the cytosolic phospholipase A2 enzymes are provided which are of use in controlling a wide variety of inflammatory diseases. The inhibitors of the present invention have the general formula where X, Z, R1, R2, R3, R4, Raand Rbare as defined in the specification.